Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

ed on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries, including England, Wales, Italy, Finland, Ireland, the Netherlands and Spain; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study, including the timing of availability of such results, and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
(Date:8/4/2015)... , Aug. 4, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that ... second quarter, ended June 30, 2015, after market close ... conference call on Thursday, August 13, 2015, at 8:00 ... China Standard Time) to review the Company,s financial results ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences Corporation (Nasdaq: ... Development Agreement (JDA) to work on the production of microbial oils ... operational capabilities to advance the development of a step-change technology for ... Under the terms of the multi-year agreement, Martek and BP ...
... , QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrinology and oncology, today reported financial and ... ended June 30, 2009. , , , ... - Two poster presentations at the American Association of Cancer, ...
... , SANTA MONICA, Calif. and LAS VEGAS, ... one of the largest umbilical cord blood stem cell preservation companies ... the life saving potential of stem cells to families nationwide and ... square foot facility in Las Vegas for conversion into a state-of-the-art ...
Cached Biology Technology:BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 7AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 8Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 2Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 3
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... CORVALLIS, Ore. Most large, clinical trials of vitamin ... no value or even harmful, have a flawed methodology ... value of these micronutrients, a new analysis suggests. ... naturally available in the human diet the same way ...
... to sequence the DNA of plants and animals has ... of DNA poses difficulties for sequencing specimens in museum ... issues, a recent study of 31 target spider species ... both time and body size are significant factors in ...
... flagship and charismatic species, very attractive for the ... relevant sentinel of the marine realm. Their,presence and ... indicate the health of the place, whereas,their disappearance, ... or health could,reflect negative environmental changes, whether of ...
Cached Biology News:Most clinical studies on vitamins flawed by poor methodology 2Most clinical studies on vitamins flawed by poor methodology 3The value of museum collections for development of DNA barcode libraries 2DNA barcoding to monitor marine mammal genetic diversity 2
... to rapidly and reliably amplify unknown ... APA Technology. APAgene provides hassle-free, ready-to ... price. All necessary ingredients are provided ... can be used for identifying transgene/genomic ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: